A phase 1 study of K-912, nonrandomized, open label, dose escalation study in Japanese patients with solid tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2017
At a glance
- Drugs Epirubicin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kowa
- 04 Jan 2017 Results published in the Investigational New Drugs
- 17 Oct 2016 Status changed from active, no longer recruiting to completed.
- 09 Sep 2016 Status changed from recruiting to active, no longer recruiting.